Search - tctmd.com

Displaying 241 - 260 of 306

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Todd Neale

August 18, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

New-Generation DES Work Just Fine in Women With Acute MI

Todd Neale

June 29, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Michael O'Riordan

May 10, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

Shelley Wood

March 01, 2017

News Daily News

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Shelley Wood

February 24, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Advertisement

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

TCTMD’s Top 10 Most Popular Stories for July 2017

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

New-Generation DES Work Just Fine in Women With Acute MI

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

TCTMD’s Top 10 Most Popular Stories for May 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

TCTMD’s Top 10 Most Popular Stories for April 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

TCTMD’s Top 10 Most Popular Stories for February 2017

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content